- Published on
Emergency and Acute Medicine – Brugada Syndrome
Overview And Definitions
Brugada syndrome is an inherited cardiac channelopathy caused by mutations in cardiac sodium (Na⁺) channels, occurring in the absence of structural heart disease. It carries a very high risk of sudden cardiac death, typically due to ventricular fibrillation. Two-year mortality approaches 30% without intervention. The condition accounts for 40–60% of cases previously labeled idiopathic ventricular fibrillation. It is more prevalent in men, particularly those of Southeast Asian descent, but can affect all ages, sexes, and races.
Etiology And Pathophysiology
Brugada syndrome is inherited in an autosomal dominant pattern in approximately 50% of cases, with variable penetrance. More than 70 sodium channel mutations have been identified, most involving the SCN5A gene, which accounts for roughly 20% of cases. The abnormal sodium current predisposes to malignant ventricular dysrhythmias, especially under triggering conditions such as fever, metabolic derangements, or drug exposure.
Clinical Presentation
Patients most commonly present with syncope, near-syncope, palpitations, or sudden cardiac arrest due to polymorphic ventricular tachycardia or ventricular fibrillation. Episodes often occur at rest or during sleep. A history may reveal nocturnal agonal respirations, fever-associated symptoms, cocaine use, or exposure to tricyclic antidepressants or psychotropic drugs. Family history is critical and may include unexplained drowning, early or sudden cardiac death, or known Brugada syndrome in relatives. Physical examination is usually normal but should focus on excluding alternative causes of syncope or dysrhythmia.
Diagnostic Evaluation
A 12-lead ECG is essential. Toxicology screening and careful history and family assessment are required. Laboratory studies should evaluate electrolytes, metabolic abnormalities, and ischemia when appropriate.
Electrocardiographic Findings
Diagnosis is based on characteristic ECG patterns in the right precordial leads (V1–V3), often with right bundle branch block or incomplete right bundle branch block morphology and ST-segment elevation.
Type 1 (coved pattern) shows ≥2 mm ST elevation with a downsloping, concave ST segment and a negative symmetric T wave, without QRS duration mismatch between V1 and V6.
Type 2 (saddleback pattern) shows an r′ ≥2 mm followed by convex ST elevation and a QRS duration mismatch between V1 and V6. ST elevation may be limited to V1 and rarely extends to V3.
Additional Testing
Laboratory testing includes serum chemistries, cardiac biomarkers if ischemia is suspected, CBC in syncope evaluation, and D-dimer when pulmonary embolism is considered. Chest radiography assesses cardiomegaly, and CT angiography is used selectively. Electrophysiology testing with sodium channel blocker challenge may unmask diagnostic ECG changes. Implantable cardioverter-defibrillator (ICD) placement dramatically reduces mortality.
Differential Diagnosis
Consider other causes of syncope and dysrhythmia, including vasovagal syncope, hypovolemia, pregnancy, atrial and ventricular tachyarrhythmias, Wolff–Parkinson–White syndrome, long QT syndromes, high-grade AV block, symptomatic bradycardia, and drug overdose (especially TCAs). ECG mimics include isolated RBBB, athletic heart changes, septal hypertrophy, pectus excavatum, arrhythmogenic right ventricular cardiomyopathy, STEMI, myocarditis, pericarditis, electrolyte disorders, and pulmonary embolism.
Management And Emergency Care
Initial management follows standard airway, breathing, and circulation principles, with full ACLS protocols for arrest or unstable dysrhythmias. Continuous cardiac monitoring is required. Cardiology consultation for electrophysiology evaluation is essential. Electrolyte and metabolic abnormalities should be corrected promptly. Antiarrhythmic medications are generally ineffective. Management of asymptomatic patients remains controversial, though EP evaluation is recommended.
Disposition And Follow-Up
Patients with concerning ECG findings, unexplained syncope, ongoing dysrhythmias, or inability to obtain urgent cardiology follow-up should be admitted. Discharge may be considered only if the patient is asymptomatic, hemodynamically stable, and cleared by cardiology, including appropriate ICD interrogation if present. All patients with suspected or confirmed Brugada syndrome require electrophysiology follow-up.
Key Clinical Insights And Diagnostic Traps
Maintain suspicion for Brugada syndrome in cases of unexplained syncope or sudden cardiac death, particularly with a relevant family history. The ECG pattern—RBBB or incomplete RBBB with ST elevation isolated to V1–V3—is central to diagnosis, but several mimics exist. Fever, systemic illness, or drugs may unmask the Brugada pattern. Early cardiology involvement is critical, as ICD implantation is the only proven therapy that nearly eliminates the risk of sudden cardiac death.
Overview And Definitions
Brugada syndrome is an inherited cardiac channelopathy caused by mutations in cardiac sodium (Na⁺) channels, occurring in the absence of structural heart disease. It carries a very high risk of sudden cardiac death, typically due to ventricular fibrillation. Two-year mortality approaches 30% without intervention. The condition accounts for 40–60% of cases previously labeled idiopathic ventricular fibrillation. It is more prevalent in men, particularly those of Southeast Asian descent, but can affect all ages, sexes, and races.
Etiology And Pathophysiology
Brugada syndrome is inherited in an autosomal dominant pattern in approximately 50% of cases, with variable penetrance. More than 70 sodium channel mutations have been identified, most involving the SCN5A gene, which accounts for roughly 20% of cases. The abnormal sodium current predisposes to malignant ventricular dysrhythmias, especially under triggering conditions such as fever, metabolic derangements, or drug exposure.
Clinical Presentation
Patients most commonly present with syncope, near-syncope, palpitations, or sudden cardiac arrest due to polymorphic ventricular tachycardia or ventricular fibrillation. Episodes often occur at rest or during sleep. A history may reveal nocturnal agonal respirations, fever-associated symptoms, cocaine use, or exposure to tricyclic antidepressants or psychotropic drugs. Family history is critical and may include unexplained drowning, early or sudden cardiac death, or known Brugada syndrome in relatives. Physical examination is usually normal but should focus on excluding alternative causes of syncope or dysrhythmia.
Diagnostic Evaluation
A 12-lead ECG is essential. Toxicology screening and careful history and family assessment are required. Laboratory studies should evaluate electrolytes, metabolic abnormalities, and ischemia when appropriate.
Electrocardiographic Findings
Diagnosis is based on characteristic ECG patterns in the right precordial leads (V1–V3), often with right bundle branch block or incomplete right bundle branch block morphology and ST-segment elevation.
Type 1 (coved pattern) shows ≥2 mm ST elevation with a downsloping, concave ST segment and a negative symmetric T wave, without QRS duration mismatch between V1 and V6.
Type 2 (saddleback pattern) shows an r′ ≥2 mm followed by convex ST elevation and a QRS duration mismatch between V1 and V6. ST elevation may be limited to V1 and rarely extends to V3.
Additional Testing
Laboratory testing includes serum chemistries, cardiac biomarkers if ischemia is suspected, CBC in syncope evaluation, and D-dimer when pulmonary embolism is considered. Chest radiography assesses cardiomegaly, and CT angiography is used selectively. Electrophysiology testing with sodium channel blocker challenge may unmask diagnostic ECG changes. Implantable cardioverter-defibrillator (ICD) placement dramatically reduces mortality.
Differential Diagnosis
Consider other causes of syncope and dysrhythmia, including vasovagal syncope, hypovolemia, pregnancy, atrial and ventricular tachyarrhythmias, Wolff–Parkinson–White syndrome, long QT syndromes, high-grade AV block, symptomatic bradycardia, and drug overdose (especially TCAs). ECG mimics include isolated RBBB, athletic heart changes, septal hypertrophy, pectus excavatum, arrhythmogenic right ventricular cardiomyopathy, STEMI, myocarditis, pericarditis, electrolyte disorders, and pulmonary embolism.
Management And Emergency Care
Initial management follows standard airway, breathing, and circulation principles, with full ACLS protocols for arrest or unstable dysrhythmias. Continuous cardiac monitoring is required. Cardiology consultation for electrophysiology evaluation is essential. Electrolyte and metabolic abnormalities should be corrected promptly. Antiarrhythmic medications are generally ineffective. Management of asymptomatic patients remains controversial, though EP evaluation is recommended.
Disposition And Follow-Up
Patients with concerning ECG findings, unexplained syncope, ongoing dysrhythmias, or inability to obtain urgent cardiology follow-up should be admitted. Discharge may be considered only if the patient is asymptomatic, hemodynamically stable, and cleared by cardiology, including appropriate ICD interrogation if present. All patients with suspected or confirmed Brugada syndrome require electrophysiology follow-up.
Key Clinical Insights And Diagnostic Traps
Maintain suspicion for Brugada syndrome in cases of unexplained syncope or sudden cardiac death, particularly with a relevant family history. The ECG pattern—RBBB or incomplete RBBB with ST elevation isolated to V1–V3—is central to diagnosis, but several mimics exist. Fever, systemic illness, or drugs may unmask the Brugada pattern. Early cardiology involvement is critical, as ICD implantation is the only proven therapy that nearly eliminates the risk of sudden cardiac death.
0 Comments
